eXoZymes (EXOZ)
NASDAQ:EXOZ
EXOZ Stock Chart & Stats
$11.49
--
Market closed
$11.49
--
Day’s Range― - ―
52-Week Range$7.08 - $18.40
Previous CloseN/A
VolumeN/A
Average Volume (3M)2.40K
Market Cap
N/A
Enterprise Value$82.50M
Total Cash (Recent Filing)$3.04M
Total Debt (Recent Filing)$1.24M
Price to Earnings (P/E)―
Beta1.24
Next Earnings
May 18, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.32
Shares Outstanding8,478,992
10 Day Avg. Volume1,191
30 Day Avg. Volume2,398
Financial Highlights & Ratios
PEG Ratio-0.19
Price to Book (P/B)26.89
Price to Sales (P/S)0.00
P/FCF Ratio-13.69
Enterprise Value/Market Cap10.00T>
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Platform Scalability & PurityA successful 100L pilot with high conversion, yield and pharma-grade purity materially de-risks scale-up for the exozyme cell-free platform. This durable technical validation supports partner supply, shortens commercialization pathways and strengthens long-term business development prospects.
Improved Investor CommunicationsRefreshing and circulating a focused investor presentation is a structural improvement in governance and capital-market engagement. Clearer strategy messaging can materially ease future fundraising, improve investor alignment, and sustain access to partnership or licensing capital over multiple financing cycles.
Modest Balance-sheet LeverageWith low absolute debt relative to shareholders' equity, the company retains some financial flexibility versus highly levered peers. This manageable leverage reduces near-term creditor pressure and gives management more options for structuring partnerships or staged financings while pursuing commercialization.
Bears Say
Pre-revenue With Widening LossesBeing pre-revenue with materially larger net losses in 2025 signals structural reliance on external capital until commercial sales begin. Sustained operating losses limit the company's ability to self-fund development and raise the risk that future financing will be dilutive or conditional, affecting long-term shareholder value.
Persistent Negative Cash GenerationConsistent negative operating and free cash flow requires recurring external funding to sustain R&D and operations. Over months to years this structural cash burn increases dilution risk, shortens runway absent deals or capital, and constrains multi-year planning for commercialization and partner commitments.
Eroding Equity And Asset BaseA sharp decline in stockholders' equity and total assets materially weakens the company's financial cushion. Reduced capital reserves make the firm more dependent on market financing, increase vulnerability to adverse shocks, and can impair negotiating leverage with partners and lenders over a multi-month horizon.
eXoZymes News
EXOZ FAQ
What was eXoZymes’s price range in the past 12 months?
eXoZymes lowest stock price was $7.08 and its highest was $18.40 in the past 12 months.
What is eXoZymes’s market cap?
Currently, no data Available
When is eXoZymes’s upcoming earnings report date?
eXoZymes’s upcoming earnings report date is May 18, 2026 which is in 41 days.
How were eXoZymes’s earnings last quarter?
eXoZymes released its earnings results on Mar 31, 2026. The company reported -$0.316 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.316.
Is eXoZymes overvalued?
According to Wall Street analysts eXoZymes’s price is currently Overvalued.
Does eXoZymes pay dividends?
eXoZymes does not currently pay dividends.
What is eXoZymes’s EPS estimate?
eXoZymes’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does eXoZymes have?
eXoZymes has 8,478,992 shares outstanding.
What happened to eXoZymes’s price movement after its last earnings report?
eXoZymes reported an EPS of -$0.316 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 12.383%.
Which hedge fund is a major shareholder of eXoZymes?
Currently, no hedge funds are holding shares in EXOZ
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
eXoZymes
eXoZymes, Inc. operates as a synthetic biochemical company in the United States. The company develops SimplePath, a platform that produces chemicals, including pharmaceuticals, fuels, materials, food additives, and novel compounds. Its platform also comprises one or more module which consist of one or more enzymes that work together to perform a defined biocatalytic conversion. The company was founded in 2014 and is headquartered in Monrovia, California.
EXOZ Earnings Call
Q4 2026
0:00 / 0:00
Technical Analysis
Ownership Overview
16.46% Insiders
0.49% Mutual Funds
― Other Institutional Investors
82.71% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---